DataMEDS AI completed the acquisition of Helomics Corp., an AI-driven cancer diagnostics lab, for $1.5 million. This strategic move propels DataMEDS into the $40 billion oncology market, diversifying its services beyond GLP-1 and Long COVID, and has led to a significant pre-market stock surge.
DataMEDS AI (MEDS) announced the completion of its acquisition of Helomics Corp., an AI-driven cancer diagnostics laboratory, from Axe Compute Inc. (AGPU) for $1.5 million. This is a significant strategic shift for DataMEDS, moving it into the lucrative $40 billion U.S. cancer diagnostic and treatment market, expanding beyond its current focus on GLP-1 agonist side effects and Long COVID. The market reacted very positively, with MEDS shares surging over 65% pre-market, indicating strong investor approval of this diversification and growth strategy. For traders, this presents a short-term opportunity in MEDS due to the immediate positive sentiment and potential for long-term growth if the oncology expansion is successful, though its small market cap and previous significant decline (97.64% over 12 months) suggest high volatility and risk. AGPU, as the seller, retains a shareholder position, making its impact more neutral but potentially benefiting from Helomics' future success under DataMEDS.